The AMPLICOR HIV-1 MONITOR� Product Portfolio

Roche Diagnostics has used the Nobel Prize-winning PCR technology to develop a comprehensive portfolio of products for use in the qualitative and quantitative testing of a wide range of disease causing organisms. This range includes HIV-1 and many of the opportunistic pathogens that affect individuals with compromised immune systems, for example, hepatitis C virus, cytomegalovirus, chlamydia trachomatis and tuberculosis. The AMPLICOR HIV-1 MONITOR� Product Portfolio range comprises not just the testing kits themselves, but hardware to automate the key procedures involved in quantitation.

The AMPLICOR HIV-1 MONITOR� has the ability to detect extremely low levels of circulating HIV-1, down to 50 copies/ml. This sensitivity enables physicians to accurately quantitate and monitor HIV-1 viral load, even specificity of the AMPLICOR PCR tests, which provide a low rate of false-positive results that might result in unnecessary treatment changes. The AMPLICOR HIV-1 MONITOR Test v 1.5 features a new primer set designed to ensure reliable detection of non-B subtypes (HIV-1 Group-M) and the sensitivity, reliability and specificity of the AMPLICOR HIV-1 MONITOR� Test has resulted in its use by the FDA to evaluate the performance of 14 of the last 18 antiretroviral agents accepted for approval in the USA. As the only FDA-approved HIV-1 RNA assay, the AMPLICOR HIV-1 MONITOR� Test has become the gold standard in HIV-1 viral load testing and is now found in 8 of 10 laboratories worldwide.

The AMPLICOR HIV-1 MONITOR� Test provides results that empower physicians and people living with HIV-1, to determine the best possible course of treatment.

Click here for additional information on the performance of AMPLICOR HIV-1 MONITOR^tm in relation to sensitivity, specificity, subtypes, reliability, clinical recognition and the AMPLICOR� testing method.